Reversibility of trastuzumab cardiotoxicity: is the concept alive and well?
Michael S
MS
Ewer
Elizabeth
E
Tan-Chiu
D018943:Anthracyclines / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy; D004357:Drug Synergism; D005260:Female; D005500:Follow-Up Studies; D006331:Heart Diseases / Q000139:chemically induced*; D006801:Humans; D000068878:Trastuzumab
D018943:Anthracyclines; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068878:Trastuzumab